Evidence map›Paper›PMID 42283139›Full record

ArticleVeterinary and comparative oncology2026

Use of the IlluminOss Photodynamic Bone Stabilisation System Following Stereotactic Body Radiation Therapy for Limb-Sparing in Six Dogs With Presumptive Appendicular Osteosarcoma.

Emily A Pope, Vincent A Wavreille, Janis L Lapsley, Eric M Green, William C Kisseberth, Robert Rabiner, Laura E Selmic

Abstract read
In one paragraph

Article in Veterinary and comparative oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emily A PopeDepartment of Veterinary Clinical Sciences, The Ohio State University Veterinary Medical Center, Columbus, Ohio, USA.
Vincent A WavreilleDepartment of Veterinary Clinical Sciences, The Ohio State University Veterinary Medical Center, Columbus, Ohio, USA.
Janis L LapsleyDepartment of Veterinary Clinical Sciences, The Ohio State University Veterinary Medical Center, Columbus, Ohio, USA.
Eric M GreenDepartment of Veterinary Clinical Sciences, The Ohio State University Veterinary Medical Center, Columbus, Ohio, USA.
William C KisseberthDepartment of Veterinary Clinical Sciences, The Ohio State University Veterinary Medical Center, Columbus, Ohio, USA.
Robert RabinerIlluminOss Medical, East Providence, Rhode Island, USA.
Laura E SelmicDepartment of Veterinary Clinical Sciences, The Ohio State University Veterinary Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0001-6695-6273

Funding

Ohio State University
6 · The paper itself

Abstract

Osteosarcoma is the most common primary bone tumour in dogs, with approximately 75% of cases occurring in the appendicular skeleton. Standard-of-care therapy consists of limb amputation followed by carboplatin chemotherapy. A minority of dogs have limb-sparing treatments including stereotactic body radiation therapy (SBRT) or surgery. SBRT has a high incidence of pathologic fracture (41%-80% of cases) following treatment, which often results in amputation or euthanasia. Prophylactic bone stabilisation following SBRT has not been recommended due to high complication rates. The IlluminOss system (IS) is an intramedullary implant consisting of a light-curable polymer within an inflatable balloon catheter, which is approved in humans for traumatic fractures and prevention of fractures secondary to bone metastases. We performed a study to assess the safety and feasibility of using the IS following SBRT in six dogs with suspected appendicular osteosarcoma. The IS was placed the day after completion of SBRT. Five of six dogs received adjuvant carboplatin chemotherapy. The IS was well tolerated with no implant-associated infections or immediate post-operative complications occurring. Pathologic fractures occurred in four dogs with a median fracture-free interval of 107 days. Three dogs ultimately underwent amputation due to pathologic fractures. No other post-operative complications occurred. The median survival time was 156 days. These findings suggest that the IS may be a palliative option for dogs following SBRT, but further research to optimise use in the dog and evaluation of the use of the IS with ancillary fixation is necessary.

Indexed as

Bone NeoplasmsDog DiseasesOsteosarcomaRadiosurgeryAnimalsAntineoplastic AgentsDogsFemaleMaleAntineoplastic Agentsfractureslimb‐sparingosteosarcomaradiosurgery

Identifiers

PMID42283139
PMCPMC13456591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.